Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells

• Published in: Anticancer research 2017-07, Vol.37 (7), p.3933-3939
• Main Authors: Ishii, Fuminori, Yoshida, Yoichiro, Yamauchi, Yasushi, Aisu, Naoya, Kojima, Daibo, Mera, Toshiyuki, Kato, Daisuke, Tanaka, Toshihiro, Naito, Keiko, Yasumoto, Kosei, Kamigaki, Takashi, Goto, Shigenori, Hamada, Yoshihiro, Nimura, Satoshi, Kodama, Shohta, Hasegawa, Suguru
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab - administration & dosage; Bevacizumab - therapeutic use; Colorectal Neoplasms - therapy; Combined Modality Therapy; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Female; Fluorouracil - administration & dosage; Fluorouracil - analogs & derivatives; Fluorouracil - therapeutic use; Hepatectomy; Humans; Immunotherapy, Adoptive - methods; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Male; Middle Aged; T-Lymphocyte Subsets - transplantation; Treatment Outcome
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.11776

Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectal liver metastases (CLM) after chemoimmunotherapy using activated αβ T-cells. From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded αβ T-lymphocytes as first-line chemoimmunotherapy were included. The median age of the five patients (two men, three women) was 61.4 (range=56-75) years. The surgical procedure was partial hepatectomy in two, laparoscopic partial hepatectomy in two, and one case of partial hepatectomy with subsegmentectomy. There was no postoperative complication of Clavien-Dindo grade 3A or higher. One patient had multiple lung metastases. Hepatectomy after chemoimmunotherapy using activated αβ T-cells for CLM can be performed safely.